Alnylam Pharmaceuticals Inc. Q3 Loss Increases, but beats estimates

Alnylam Pharmaceuticals Inc. (ALNY) reported Loss for its third quarter that increased from the same period last year and missed the Street estimates.

The company's bottom line came in at -$405.92 million, or -$3.32 per share. This compares with -$204.51 million, or -$1.72 per share, in last year's third quarter.

Excluding items, Alnylam Pharmaceuticals Inc. reported adjusted earnings of -$193.37 million or -$1.58 per share for the period.

Analysts on average had expected the company to earn -$1.77 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 40.9% to $264.31 million from $187.63 million last year.

Alnylam Pharmaceuticals Inc. earnings at a glance (GAAP) :

-Earnings (Q3): -$405.92 Mln. vs. -$204.51 Mln. last year.
-EPS (Q3): -$3.32 vs. -$1.72 last year.
-Analyst Estimate: -$1.77
-Revenue (Q3): $264.31 Mln vs. $187.63 Mln last year.

For comments and feedback contact: editorial@rttnews.com

Follow RTT